OTCQX
RHHVF

Roche Holding AG Participation

Drug Manufacturers-General
Healthcare

Prices are adjusted according to historical splits.

Roche Holding AG Participation Stock Price

Vitals

Today's Low:
$282.88
Today's High:
$288.11
Open Price:
$286.044
52W Low:
$270.0832
52W High:
$336.9892
Prev. Close:
$284.93
Volume:
6881

Company Statistics

Market Cap.:
$230.26 billion
Book Value:
33.2
Revenue TTM:
$63.14 billion
Operating Margin TTM:
31.09%
Gross Profit TTM:
$47.83 billion
Profit Margin:
17.47%
Return on Assets TTM:
14.34%
Return on Equity TTM:
40.25%

Company Profile

Roche Holding AG Participation had its IPO on under the ticker symbol RHHVF.

The company operates in the Healthcare sector and Drug Manufacturers-General industry. Roche Holding AG Participation has a staff strength of 103,613 employees.

Stock update

Shares of Roche Holding AG Participation opened at $286.04 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $282.88 - $288.11, and closed at $286.52.

This is a +0.56% increase from the previous day's closing price.

A total volume of 6,881 shares were traded at the close of the day’s session.

In the last one week, shares of Roche Holding AG Participation have slipped by -1.96%.

Roche Holding AG Participation's Key Ratios

Roche Holding AG Participation has a market cap of $230.26 billion, indicating a price to book ratio of 9.5743 and a price to sales ratio of 3.9696.

In the last 12-months Roche Holding AG Participation’s revenue was $63.14 billion with a gross profit of $47.83 billion and an EBITDA of $23.00 billion. The EBITDA ratio measures Roche Holding AG Participation's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Roche Holding AG Participation’s operating margin was 31.09% while its return on assets stood at 14.34% with a return of equity of 40.25%.

In Q2, Roche Holding AG Participation’s quarterly earnings growth was a negative -15.8% while revenue growth was a negative 9.7%.

Roche Holding AG Participation’s PE and PEG Ratio

Forward PE
14.1243
Trailing PE
18.5498
PEG
3.443

Its diluted EPS in the last 12-months stands at $15.36 per share while it has a forward price to earnings multiple of 14.1243 and a PEG multiple of 3.443. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Roche Holding AG Participation’s profitability.

Roche Holding AG Participation stock is trading at a EV to sales ratio of 4.4719 and a EV to EBITDA ratio of 12.474. Its price to sales ratio in the trailing 12-months stood at 3.9696.

Roche Holding AG Participation stock pays annual dividends of $9.5 per share, indicating a yield of 3.56% and a payout ratio of 69.34%.

Balance sheet and cash flow metrics

Total Assets
$84.37 billion
Total Liabilities
$26.21 billion
Operating Cash Flow
$736.50 million
Capital Expenditure
$842.50 million
Dividend Payout Ratio
69.34%

Roche Holding AG Participation ended 2024 with $84.37 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $84.37 billion while shareholder equity stood at $26.52 billion.

Roche Holding AG Participation ended 2024 with $0 in deferred long-term liabilities, $26.21 billion in other current liabilities, in common stock, $38.33 billion in retained earnings and $10.56 billion in goodwill. Its cash balance stood at $3.72 billion and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $20.35 billion.

Roche Holding AG Participation’s total current assets stands at $30.98 billion while long-term investments were $0 and short-term investments were $3.79 billion. Its net receivables were $11.09 billion compared to accounts payable of $4.06 billion and inventory worth $8.50 billion.

In 2024, Roche Holding AG Participation's operating cash flow was $736.50 million while its capital expenditure stood at $842.50 million.

Comparatively, Roche Holding AG Participation paid $0.69 in dividends in 2024.

Other key metrics

Current Trading Price
$286.52
52-Week High
$336.9892
52-Week Low
$270.0832
Analyst Target Price
$

Roche Holding AG Participation stock is currently trading at $286.52 per share. It touched a 52-week high of $336.9892 and a 52-week low of $336.9892. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $301.15 and 200-day moving average was $302.44 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 4045.8% are held by institutions.

Frequently Asked Questions About Roche Holding AG Participation

The stock symbol (also called stock or share ticker) of Roche Holding AG Participation is RHHVF

The IPO of Roche Holding AG Participation took place on

Similar Industry Stocks (Drug Manufacturers-General)

Last Price
Chg
Chg%
$28.55
0.02
+0.07%
Tata Metaliks Limited (TATAMETALI)
$957.15
-19.3
-1.98%
$143.33
2.53
+1.8%
$7.04
-0.18
-2.49%
$2488.3
-34.5
-1.37%
MSTC Ltd (MSTC)
$406.5
-20.25
-4.75%
$4.2
0.1
+2.44%
$204.85
-1
-0.49%
$97.8
-2.8
-2.78%
Indus Towers Ltd (INDUSTOWER)
$181.9
-10.75
-5.58%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. The company offers pharmaceutical products in the therapeutic areas of oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, cardiovascular, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD); and strategic agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize zilebesiran. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

Address

Konzern Hauptsitz, Basel, Switzerland, 4070